Cansortium Inc (OTC: CNTMF) is a vertically integrated multistate operator that is well-positioned for "dramatic expansion," according to Canaccord Genuity.
Bobby Burleson initiated coverage of Cansortium's Canada-listed stock with a Speculative Buy rating and $2.50 price target.
Cansortium's focus is on the medical cannabis space in Florida, where it oversees 11 dispensaries and is considered a "large player" in the regulated cannabis market, Burleson said in the Friday initiation note. (See his track record here.)
The company's market share in Florida is likely to increase from 6% in 2019 to 11% in 2020, with plans to open 19 more stores by the end of the year, the analyst said.
Part of the growth story comes from Cansortium's expansion potential in new markets, Burleson said.
The company should see initial contributions from the province of Ontario and from Michigan in the fourth quarter, he said. Coupled with the opportunity in Florida, Cansortium could address a total addressable market of $3 billion in 2020, the analyst said.
The company also faces "significant" longer-term opportunities in Pennsylvania from its application for a clinical registrant license, along with "rapidly evolving" regulations in Texas, Burleson said.
Finally, Cansortium's ongoing operations in Puerto Rico and a subsidiary in Latin America create the potential to be a first-mover in the region, according to Canaccord.
Cansortium's over-the-counter shares were 4.47% higher at $1.62 at the close Friday.
How Are New Innovations Driving The Cannabis Market Growth?
The Queen Goes Green: UK's Centre For Medicinal Cannabis Releases New Report On CBD
See more from Benzinga
- 18 Stocks Joining The Russell Indices
- Sell-Side Weighs In On Accenture's 'Steady' Quarter
- A Walgreens Analyst's Takeaways From Q3 Earnings
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.